Today: 29 April 2026
Browse Category

NASDAQ:IBRX 29 November 2025 - 16 January 2026

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
··
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

The European Medicines Agency’s CHMP issued a positive opinion recommending conditional marketing authorization for ImmunityBio’s Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. IBRX shares closed at $2.36 on Dec. 12, up 7.76% on heavy volume, and traded near $2.39 pre-market Dec. 15. The European Commission has not yet given final approval.
15 December 2025
··
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio shares surged up to 13% on November 28 after reporting Q3 revenue of $32.1 million, up from $6.1 million a year earlier, driven by Anktiva sales. The company posted a Q3 net loss of $67.3 million and a nine-month cash outflow of $234.6 million. Anktiva is FDA-approved for certain bladder cancer patients in the U.S. and recently gained UK approval. Shares remain down mid-teens for the year.
29 November 2025
···
1 2

Stock Market Today

  • Verisk Analytics Q1 Earnings and Revenues Beat Estimates, Shares Lagging Year-To-Date
    April 29, 2026, 10:21 AM EDT. Verisk Analytics (VRSK) reported Q1 earnings of $1.82 per share, surpassing the Zacks Consensus Estimate of $1.76 and representing a 3.49% earnings surprise. Revenues rose to $782.6 million, also beating expectations. Despite consistent beats over the past four quarters, shares have dropped about 21% year-to-date versus a 4.3% gain in the S&P 500. The stock holds a Zacks Rank #3 (Hold), suggesting performance in line with the market. Investors await management's guidance for clues on future momentum. The Business - Information Services sector ranks in the top 16% of over 250 Zacks industries, indicating potential support amid mixed earnings estimate revisions.

Latest article

Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

Western Digital Stock Jumps Before Earnings as AI Storage Demand Gets a Seagate Boost

29 April 2026
Western Digital shares rose 9.3% to $427.45 Wednesday after Seagate’s quarterly forecast topped estimates and sent storage stocks higher. Seagate shares jumped 16.6%. Seagate projected fourth-quarter revenue of $3.45 billion and non-GAAP earnings of $5 a share. Western Digital will report fiscal third-quarter results after markets close Thursday.
Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

29 April 2026
Generac Holdings raised its 2026 sales outlook after first-quarter net sales rose 12% and commercial and industrial sales jumped 28% to $510 million, driven by data center demand. Shares climbed 11% after adjusted earnings of $1.80 a share beat estimates. The company now expects full-year net sales growth in the mid-to-high teens percentage range, up from its prior forecast. Generac also increased its adjusted EBITDA margin guidance.
Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

29 April 2026
Lemonade Inc reported first-quarter revenue of $258 million, up 71% from a year earlier, and narrowed its net loss to $35.8 million, or 47 cents a share. Shares rose 5.6% in premarket trading after results beat estimates. In-force premium climbed 32% to $1.33 billion, with customers up 23% to 3.14 million. The company raised its 2026 outlook and now expects full-year revenue of up to $1.203 billion.
Go toTop